Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Impax Laboratories Inc's Impax Pharmaceuticals And Glaxosmithkline Plc Terminate Collaboration On IPX066 (RYTARYTM)


Monday, 29 Apr 2013 08:00am EDT 

Impax Laboratories Inc's Impax Pharmaceuticals and Glaxosmithkline Plc announced that they are terminating their collaboration for the development and commercialization of IPX066 outside the United States (U.S.) and Taiwan. IPX066 (known as RYTARY in the U.S.) is an investigational extended-release capsule formulation of carbidopa-levodopa being developed for the symptomatic treatment of adult patients with idiopathic Parkinson's disease and is not approved anywhere in the world. Under the terms of the agreement entered into in December 2010, GSK's right to develop and commercialize IPX066 outside the U.S. and Taiwan will transfer back to Impax effective at the end of July 2013. The decision has been reached because of delays in the anticipated regulatory approval and launch dates in countries in which GSK has rights to commercialize the product. Impax intends to initiate activities to find a partner or partners for markets outside the U.S. looking to grow their non-US neurology franchise.